| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:38 | Moleculin Biotech, Inc.: Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) | 18 | PR Newswire | - Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin
HOUSTON, May 15, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX)... ► Artikel lesen | |
| Di | Earnings call: Moleculin Biotech optimistic on Annamycin's future | 2 | Investing.com | ||
| Mo | Moleculin Biotech GAAP EPS of -$2.02 | 1 | Seeking Alpha | ||
| Mo | Moleculin Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mo | Moleculin Biotech, Inc.: Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update | 119 | PR Newswire | - Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13)
-... ► Artikel lesen | |
| Sa | Moleculin Biotech Inc reports results for the quarter ended in January - Earnings Summary | 1 | Reuters | ||
| Fr | Moleculin Biotech, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 02.05. | Moleculin Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.05. | Moleculin Biotech, Inc.: Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin | 46 | PR Newswire | - Company appoints internationally renowned clinician, Martin S. Tallman, MD as inaugural clinician member HOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin... ► Artikel lesen | |
| 26.04. | Moleculin Biotech, Inc. - 10-K/A, Annual Report | 4 | SEC Filings | ||
| 25.04. | JTC Team, LLC: Moleculin Biotech Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team | 339 | ACCESSWIRE | Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 / JTC Team ("JTC"), a fully... ► Artikel lesen | |
| 25.04. | Moleculin Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.04. | Moleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AML | 3 | RTTNews | ||
| 18.04. | Moleculin Biotech, Inc.: European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) | 63 | PR Newswire | - Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML subjects... ► Artikel lesen | |
| 18.04. | Moleculin Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.04. | Moleculin Biotech Reveals Positive Anti-cancer Data For Annamycin With Non-cardiotoxic Effects | 2 | RTTNews | ||
| 10.04. | Moleculin Biotech, Inc.: Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties | 156 | PR Newswire | Annamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against established cardiomyocyte culturesResults clearly aligned with lack of drug-related... ► Artikel lesen | |
| 08.04. | Moleculin Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.03. | Moleculin Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.03. | Earnings call: Moleculin Biotech spotlights Annamycin progress in 2023 call | 9 | Investing.com |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 7.668 |
| EVOTEC | 6.223 |
| PLUG POWER | 5.959 |
| TUI | 5.804 |
| AMC ENTERTAINMENT | 4.449 |
| NEL | 4.373 |
| BAYER | 4.164 |
| RHEINMETALL | 3.097 |
| SIEMENS ENERGY | 2.190 |
| NVIDIA | 1.953 |
| COMMERZBANK | 1.921 |
| NORDEX | 1.862 |
| MERCEDES-BENZ | 1.851 |
| ALIBABA | 1.801 |
| AIXTRON SE | 1.782 |
| BYD | 1.745 |
| ALLIANZ | 1.716 |
| RWE | 1.706 |
| DELIVERY HERO | 1.588 |
| THYSSENKRUPP | 1.527 |
| DEUTSCHE BANK | 1.522 |
| THYSSENKRUPP NUCERA | 1.417 |
| VOLKSWAGEN | 1.371 |
| RENK GROUP | 1.262 |
| TESLA | 1.262 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
